Draft preview · for review
← Back to site01/43
01
The one idea that changes everything.
Patient education · preview
How to achieve lasting success on weight-loss medication: the support your prescription did not come with.
A 30–40 minute presentation · Dr Chetna Patel · Thrivefully
Who this is for
Why this matters
83–88%
still on treatment at ~68 weeks, in clinical trials
33–50%
still on it at one year, in the real world
15% at two years
The medication and the dose are the same; the difference lies in the care around them. That gap is what wraparound care addresses.
Source: 2025 multi-society advisory (PMC12304835).
The reframe
The medication is the first step; it was never intended to constitute the whole plan.
What you'll take away
The first weeks.
The window of opportunity.
Keeping the result.
02
In plain terms — and grounded in published evidence rather than opinion.
The science, in plain terms
Signals fullness sooner, and for longer.
Slows how fast it empties, so you stay satisfied.
Steadies it: fewer crashes and cravings.
It changes the signals. It does not build the habits, protect your muscle, or hold the line when you stop.
Source: PMID 39114288.
This is bigger than the scale
−20%
major cardiovascular events, in people with obesity and no diabetes
~93%
lower progression to type 2 diabetes in high-risk people, over 3 years
25–29
fewer sleep-apnoea events per hour
~half
the knee-arthritis pain
Sources: PMID 37952131, 39536238, 38912654, 39476339.
Why results vary
5–18%
weight loss in clinical trials
~8–11%
in the real world
What varies between the two is the support around the medication.
Source: 2025 advisory (PMC12304835).
It's consensus, not opinion
Sources: PMID 40445127, 41502845.
The gap
The medication is widely prescribed; the structured support around it is less consistently provided.
03
Prepare, support, maintain — and the trap in each.
Phase 1 · Prepare
The first weeks decide whether you make it to the good part.
What's happening
The trap
Sources: PMID 39037780, 38286487.
What to actually do
Source: PMID 38241775.
Why not fully DIY
Which symptom means 'keep going' — and which means 'call today'?
Phase 2 · Support
The window of opportunity — rare, powerful, easy to waste.
The window
Trap A · Muscle — the headline
'Up to 40% of what you lose is muscle.' Real — and widely misunderstood.
The truth about 'lean mass'
Source: PMC11450469, PMID 39372917.
But take it seriously
Source: PMID 39295512.
Phase 2 · Support: the muscle module
Whole-body lean tissue lost on a calorie deficit, with and without strength training
7×
less lean tissue lost. That gap is the argument for training through the window rather than relying on diet alone.
Source: women on a 1,000 kcal/day deficit, PMC11450469. Not medical advice.
The muscle-protection prescription
Source: consensus PMC12768930, PMC11611443.
Trap B · Nutrition
Source: 2025 advisory (PMC12304835).
Trap C · Habits
Source: PMID 38015216.
The pattern
Why not fully DIY
Measure your own body composition? Programme your own training? For a year?
Phase 3 · Maintain
Maintaining results after treatment
The cliff
~two-thirds
of the lost weight regained within a year of stopping
Reverts too
blood pressure and blood sugar tend to drift back
If this phase is lost, the health benefits are lost with the weight.
Sources: PMID 35441470, 40507553.
The reframe
Source: PMID 38078870.
What to do
Why not fully DIY
The hardest moments come late — exactly when most people are on their own.
04
Add up the traps.
The DIY reality
…plus your own accountability coach, for 12–24 months. That is not a willpower problem. It is a systems problem.
The model already exists
The cost of getting it wrong
The positive position
Each of these pitfalls has an evidence-based response: structured, doctor-led, matched to your phase.
05
Wraparound care — and your next step.
What wraparound care is
How we do it
Non-prescribing by design — we do not sell the medication, so our advice remains about you.
The takeaway
Educational preview. Not medical advice. Every figure is drawn from peer-reviewed research and is pending final clinical sign-off.